End-of-day quote
JAMAICA STOCK EXCHANGE
23:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
2.65
JMD
|
0.00%
|
|
+1.53%
|
-14.24%
|
Fiscal Period: Oktober |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,131
|
3,598
|
4,531
|
4,184
|
4,184
|
Enterprise Value (EV)
1 |
4,024
|
4,172
|
5,177
|
4,765
|
4,830
|
P/E ratio
|
31.5
x
|
17.4
x
|
25
x
|
19
x
|
19.6
x
|
Yield
|
-
|
5.19%
|
3.24%
|
3.6%
|
3.61%
|
Capitalization / Revenue
|
5.66
x
|
4.7
x
|
5.35
x
|
4.46
x
|
3.96
x
|
EV / Revenue
|
5.52
x
|
5.45
x
|
6.11
x
|
5.08
x
|
4.58
x
|
EV / EBITDA
|
27.1
x
|
18.3
x
|
21
x
|
15.8
x
|
16.7
x
|
EV / FCF
|
-952
x
|
-14.6
x
|
-84.3
x
|
42.8
x
|
65.7
x
|
FCF Yield
|
-0.11%
|
-6.84%
|
-1.19%
|
2.34%
|
1.52%
|
Price to Book
|
5.94
x
|
4.57
x
|
6.03
x
|
3.62
x
|
3.43
x
|
Nbr of stocks (in thousands)
|
1,332,537
|
1,332,537
|
1,332,537
|
1,332,537
|
1,332,537
|
Reference price
2 |
3.100
|
2.700
|
3.400
|
3.140
|
3.140
|
Announcement Date
|
12/02/20
|
28/01/21
|
13/04/22
|
10/02/23
|
31/01/24
|
Fiscal Period: Oktober |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
636.2
|
729.5
|
765.9
|
846.8
|
937.3
|
1,055
|
EBITDA
1 |
171
|
148.4
|
227.8
|
247
|
301
|
289.1
|
EBIT
1 |
157
|
136.1
|
216.5
|
230.9
|
281.7
|
270.2
|
Operating Margin
|
24.68%
|
18.66%
|
28.27%
|
27.26%
|
30.06%
|
25.6%
|
Earnings before Tax (EBT)
1 |
138
|
127.8
|
208.7
|
181.3
|
220.8
|
217.6
|
Net income
1 |
119.7
|
131
|
206.6
|
181.3
|
220.8
|
213.1
|
Net margin
|
18.82%
|
17.95%
|
26.98%
|
21.41%
|
23.56%
|
20.19%
|
EPS
2 |
0.0898
|
0.0983
|
0.1551
|
0.1361
|
0.1657
|
0.1599
|
Free Cash Flow
1 |
67.77
|
-4.226
|
-285.5
|
-61.42
|
111.4
|
73.53
|
FCF margin
|
10.65%
|
-0.58%
|
-37.28%
|
-7.25%
|
11.89%
|
6.97%
|
FCF Conversion (EBITDA)
|
39.63%
|
-
|
-
|
-
|
37.03%
|
25.43%
|
FCF Conversion (Net income)
|
56.62%
|
-
|
-
|
-
|
50.47%
|
34.51%
|
Dividend per Share
2 |
0.0800
|
-
|
0.1400
|
0.1100
|
0.1130
|
0.1133
|
Announcement Date
|
10/01/19
|
12/02/20
|
28/01/21
|
13/04/22
|
10/02/23
|
31/01/24
|
Fiscal Period: Oktober |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
575
|
647
|
581
|
645
|
Net Cash position
1 |
97.5
|
107
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
2.522
x
|
2.619
x
|
1.93
x
|
2.232
x
|
Free Cash Flow
1 |
67.8
|
-4.23
|
-286
|
-61.4
|
111
|
73.5
|
ROE (net income / shareholders' equity)
|
24.2%
|
19.2%
|
27.9%
|
24.7%
|
19.7%
|
17.9%
|
ROA (Net income/ Total Assets)
|
11.7%
|
10.5%
|
10.6%
|
8.58%
|
8.62%
|
7.88%
|
Assets
1 |
1,023
|
1,249
|
1,949
|
2,115
|
2,561
|
2,705
|
Book Value Per Share
2 |
0.5000
|
0.5200
|
0.5900
|
0.5600
|
0.8700
|
0.9100
|
Cash Flow per Share
2 |
0.0800
|
0.0900
|
0.2400
|
0.1400
|
0.1800
|
0.1900
|
Capex
1 |
1.66
|
60.3
|
431
|
35.3
|
26.4
|
14
|
Capex / Sales
|
0.26%
|
8.26%
|
56.3%
|
4.17%
|
2.81%
|
1.33%
|
Announcement Date
|
10/01/19
|
12/02/20
|
28/01/21
|
13/04/22
|
10/02/23
|
31/01/24
|
|
1st Jan change
|
Capi.
|
---|
| -14.24% | 22.7M | | -0.78% | 24.26B | | +15.06% | 8.74B | | +1.47% | 8.21B | | -31.14% | 6.87B | | +18.74% | 5.29B | | +1.10% | 4.13B | | -9.24% | 3.79B | | -8.91% | 3.34B | | +7.11% | 3.2B |
Pharmaceuticals Wholesale
|